Osteosarcome Immunotherapy Induced By Fusion Cells From B Lymphocytes And Osteosarcoma Cells

Osteosarcoma Immunotherapy Induced by Fusion Cells from B Lymphocytes and Osteosarcoma CellsPostgraduate: Peng lei Supervisor: Wang -qingliang Wang zhenAlong with the development of cancer research, the traditional operation scheme have been changed in many ways, that makes the local control of Osteosarcoma become possible. But the almost 40% lung metastasis tends to result in treatment failure in spite of combined with radiotherapy and chemotherapy.The findings of tumor specific antigen recognized by CTL, especially the melanoma antigens MAGE and MART, have promoted the active immunotherapy in large extent and then several clinical trails are hi progress. The immunotherapy based on a greater appreciation of the mechanisms by which tumor-specific cytolytic cells are generated is becoming a new approach in cancer treatment.Central to the induction of CTL responses are professional antigen-presenting cells, including macrophages and dendritic cells, which present tumor antigen to the immune system in the context of major histocompatibility complex (MHC) class I and class II molecules.Macrohpages play an important role in tumor immunity, which can be attributed to its augmenting effect on antigen presenting and nonspecific tumoricidal potentiality. Because there are not any osteosarcoma antigens identified till now, we try to employ a new immunotherapy strategy in this study by fusing entire osteosarcoma cells with, in order to evaluate the therapeutic effectiveness of fusion tumor vaccine in osteosarcoma treatment.First, MNNG is applied to induce the mutation of osteosarcoma cell line of the C3H mice, then the HGPRT -absent cell line is positively screened by the use of 8-AG, which is called cell line LM9. Next, LM9 is fused with the activated B Ly of the C3H mice, the biologial characteristics of the fused cell and its capacity to induce tumor-specific immunological response is observed in vitro.Then the fused cell is applied to the C3H mice carrying osteosarcoma, observe its effect in prohibiting the growing of tumor,and also its ability to survive among the tumor cell.The result of the experiments demonstrat that the fused cell of mice grows slowly in vitro, and its effect to induce tumor-specific immunological response is also obvious. All of the the tumor-carrying mice which is inoculated by the fused cell survived more than 30 days. Among 8 of them, two died in the day of 38 and 45. the others survived more than 60 days. To the contrast, all the mice which are not inoculated died within 45 days(P<0.01) The moral rate of inoculated groups are obviously higher than that of the central group when they are,both attacked by the tumor cells (PO.01) .The result of the experiments in animals suggest that the fused cell may play a role in the imunological therapy of osteosarcoma.